You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The latest news on next-generation sequencing.
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.
UK-based ATDBio will develop new oligonucleotide-tagged microbeads for use in droplet-based single-cell RNA sequencing, to be evaluated by researchers at Oxford.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.
Some of the firms will receive money to speed up test development, while others will use the funds to expand their testing and manufacturing capacity.
he single-cell microbiome sequencing firm has raised a total of ¥1.5 billion in equity financing since its founding in 2018.
Created by BloodPAC members, the resource may serve as a set of generic analytical protocols to help define industry standards for developing liquid biopsy tests.
Golden Gateway, which operates throughout the Asia Pacific region, will exclusively distribute UST's linked read library preparation kit in Australia.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.